Peter Kolkhof

14PUBLICATIONS
62CO-AUTHORS
Medical infection agents (incl. prions)Epidemiological modellingNeurology and neuromuscular diseasesCharacterisation of biological macromoleculesMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 26, 2025
Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial.

Mario Berger, Aidan MacNamara, João Pedro Ferreira

|Oct 29, 2024
Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.

Muthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett

|Sep 29, 2024
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.

Misato Chimura, Mark C Petrie, Morten Schou

|Sep 01, 2024
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.

Muthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett

|Jun 11, 2024
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.

Hiddo J L Heerspink, Rajiv Agarwal, George L Bakris

|Jun 06, 2024
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.

Ixchel Lima Posada, Matthieu Soulié, Yohan Stephan

Pageof 3

Frequent Collaborators

5 joint publications

Peter Rossing

4 joint publications

Faiez Zannad

3 joint publications

Adriaan A Voors

3 joint publications

Pardeep S Jhund